Yingtai Medical announced that the board of directors of the company reviewed and approved the proposed issuance of A-shares and related matters. It is proposed to publicly issue no more than 37.2706 million A-shares, accounting for no more than 15% of the total share capital after issuance, and may be over-allotted by no more than 15% of the shares issued. The sponsor is Cathay Pacific Haitong Securities. The release plans to raise 1,800 billion yuan for projects such as medical device industrial parks, expansion, R&D, marketing network construction, and loan repayment. At the same time, the board of directors reviewed and approved the draft articles of association and governance system applicable after A-share listing, as well as revising the H share incentive trust plan to allow trustees to trade H shares through on-market or off-market transactions. The matters relating to A-shares mentioned above are subject to approval by the Extraordinary General Meeting of Shareholders and the Supervisory Authority.

Yingtai Medical announced that the board of directors of the company reviewed and approved the proposed issuance of A-shares and related matters. It is proposed to publicly issue no more than 37.2706 million A-shares, accounting for no more than 15% of the total share capital after issuance, and may be over-allotted by no more than 15% of the shares issued. The sponsor is Cathay Pacific Haitong Securities. The release plans to raise 1,800 billion yuan for projects such as medical device industrial parks, expansion, R&D, marketing network construction, and loan repayment. At the same time, the board of directors reviewed and approved the draft articles of association and governance system applicable after A-share listing, as well as revising the H share incentive trust plan to allow trustees to trade H shares through on-market or off-market transactions. The matters relating to A-shares mentioned above are subject to approval by the Extraordinary General Meeting of Shareholders and the Supervisory Authority.